Long-term effects of two different continuous combined regimens of hormone replacement therapy on well-being
2004 (English)In: Gynecological Endocrinology, ISSN 0951-3590, E-ISSN 1473-0766, Vol. 18, no 6, 305-317 p.Article in journal (Refereed) Published
Our aim was to compare the effect on well-being of two different continuous combined hormone replacement therapies (HRT) in women starting treatment (‘starters’) and women switching from mainly sequential HRT (‘switchers’). The design was a randomized, double-blind, 1-year, prospective study, including 249 postmenopausal women treated with 0.625 mg conjugated estrogen (CE)/ 5 mg medroxyprogesterone acetate (MPA) or 2 mg estradiol/1 mg norethisterone acetate (NETA) continuously. The main outcome measure was well-being, reported daily on a validated symptom scale during treatment cycles 1, 2, 6 and 13. Both treatment groups, starters and switchers, improved significantly in episodes of sweating during the first 6 months (p50.05). Women treated with estradiol/NETA experienced more breast tenderness compared to women using CE/MPA during the whole study period (p50.001), whereas there were no differences in negative mood symptoms between treatment groups. Starters experienced improved wellbeing during the whole study, whereas switchers experienced a transient improvement during the first 2 months. Overall, negative mood symptoms were more frequently reported by women with a history of premenstrual syndrome (PMS) (p50.05). Progestogen side-effects were more pronounced with estradiol/NETA than with CE/MPA combinations. Individual factors, such as previous PMS and previous HRT use, should be taken into consideration when prescribing HRT.
Place, publisher, year, edition, pages
2004. Vol. 18, no 6, 305-317 p.
Double-Blind Method, Drug Administration Schedule, Estradiol/administration & dosage, Estrogen Replacement Therapy, Estrogens; Conjugated (USP)/administration & dosage, Female, Humans, Medroxyprogesterone 17-Acetate/administration & dosage, Menopause/*psychology, Middle Aged, Norethindrone/administration & dosage/*analogs & derivatives, Prospective Studies, Quality of Life, Sweden
Obstetrics, Gynecology and Reproductive Medicine
Research subject Obstetrics and Gynaecology
IdentifiersURN: urn:nbn:se:umu:diva-9363DOI: 10.1080/09513590410001667265PubMedID: 15497493OAI: oai:DiVA.org:umu-9363DiVA: diva2:149034